| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
AJ2-30 targets SLC15A4. It inhibits SLC15A4-mediated MDP transport with an IC50 of 2.6 μM and suppresses IFN-α production with an IC50 of 1.8 μM. SLC15A4 is a transporter involved in innate immune signaling, and its inhibition modulates inflammatory responses.
|
|---|---|
| ln Vitro |
In vitro, AJ2-30 (5 μM, 24 h) inhibits TLR7, TLR7/8, and TLR9-induced IFN-α production in human plasmacytoid dendritic cells (pDCs). It also inhibits bacterial dipeptides MDP and TriDAP-mediated NOD1 and NOD2 signaling in primary human macrophages. AJ2-30 inhibits TLR9-mediated B cell activation.
|
| ln Vivo |
In vivo, AJ2-30 suppresses inflammatory cytokine production in lupus patient-derived PBMCs. It also inhibits endolysosomal TLR7-9-mediated mTOR activation. These findings support its potential for studying autoimmune and inflammatory diseases.
|
| Enzyme Assay |
SLC15A4 transport activity is measured using MDP uptake assays. AJ2-30 is incubated with SLC15A4-expressing cells, and MDP transport inhibition is measured.
|
| Cell Assay |
Cellular activity of AJ2-30 is evaluated in human plasmacytoid dendritic cells (pDCs) and primary human macrophages. Cells are treated with the compound, and IFN-α production or NOD signaling is measured.
|
| Animal Protocol |
In vivo efficacy of AJ2-30 is evaluated using PBMCs from lupus patients. Cytokine production is measured to assess the compound's immunosuppressive effects.
|
| ADME/Pharmacokinetics |
AJ2-30 has a molecular formula of C23H22N4 and a molecular weight of 354.45. Its SMILES code is CCN1C2=C(C=CC=C2)C3=CC(CNC4=NC5=C(N4C)C=CC=C5)=CC=C31. The compound is stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for AJ2-30 are limited. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| Additional Infomation |
AJ2-30 is a specific SLC15A4 inhibitor that suppresses IFN-α production and inhibits MDP transport. It blocks endogenous NOD signaling in human and mouse macrophages. It can be used for inflammation research and is a valuable tool for studying autoimmune diseases such as lupus.
|
| Molecular Formula |
C23H22N4
|
|---|---|
| Molecular Weight |
354.447584629059
|
| Exact Mass |
354.18
|
| Elemental Analysis |
C, 77.94; H, 6.26; N, 15.81
|
| CAS # |
2700322-79-6
|
| PubChem CID |
163902400
|
| Appearance |
White to off-white solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
511
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN1C2=C(C=C(C=C2)CNC3=NC4=CC=CC=C4N3C)C5=CC=CC=C51
|
| InChi Key |
QKZNLVHPKAXDOL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H22N4/c1-3-27-20-10-6-4-8-17(20)18-14-16(12-13-21(18)27)15-24-23-25-19-9-5-7-11-22(19)26(23)2/h4-14H,3,15H2,1-2H3,(H,24,25)
|
| Chemical Name |
N-((9-ethyl-9H-carbazol-3-yl)methyl)-1-methyl-1H-benzo[d]imidazol-2-amine
|
| Synonyms |
AJ2-30; AJ230; AJ2 30
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8213 mL | 14.1064 mL | 28.2127 mL | |
| 5 mM | 0.5643 mL | 2.8213 mL | 5.6425 mL | |
| 10 mM | 0.2821 mL | 1.4106 mL | 2.8213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
